Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
OC

NASDAQ · OCEAW

Ocean Biomedical, Inc.

Healthcare · Biotechnology

$0.03

Up+$0.03 (+1762.50%)

Updated Aug 23, 2026, 7:36 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.94M
P/E ratio
-0
Dividend yield
0.00%
52-week range
— – —
Volume
184.7K
Avg. volume
56.38K

Price performance

OCEAW price history

1M range · 0 trading sessions · Daily adjusted prices

OCEAW does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest OCEAW news

The latest Smart Investors Daily articles mentioning OCEAW.

Stock researchCompany · Overview

OCEAW research

Overview

Company profile and research snapshot.

Company profile

OCEAN BIOMEDIACAL INC WTS

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · May 25, 2023

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index

Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that it is expected to be added to the Russell 2000® Index, effective after the U.S. market opens on June 26, 2023. This addition is part of the annual reconstitution of the Russell stock indexes. A preliminary list of index additions, including Ocean Biomedical, was posted by FTSE Russell on May 19, 2023.

GlobeNewswire Inc. · May 23, 2023

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.

Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific co-founder, Dr. Jack A. Elias, that CHi3L1 is a “master regulator” of tumor growth in multiple visceral cancers.

GlobeNewswire Inc. · May 16, 2023

Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility

Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that it has entered into a private placement pursuant to a securities purchase agreement with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto”) for the issuance and sale of a total anticipated $25 million facility of Senior Secured Convertible Promissory Notes (the “Notes”). The Notes will be funded in multiple tranches, subject to certain conditions.

GlobeNewswire Inc. · May 1, 2023

Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that an equity analyst coverage report issued by EF Hutton has increased that firm’s price target by 70%, now targeting $17 per share, up from their initial target of $10 per share. This increase was attributed in part to the publication in Cancer Research of findings suggesting “compelling activity of Chi3L1 in animal models of glioblastoma.”

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By